Please check your internet connection and try again.
# Hyoscine butylbromide (Buscopan)
## Overview
Hyoscine butylbromide is a quaternary ammonium antispasmodic agent. Unlike hyoscine hydrobromide, it does not cross the blood-brain barrier effectively, resulting in minimal central nervous system effects. It acts as an antimuscarinic agent with a high affinity for muscarinic receptors in the gastrointestinal, biliary, and urinary tracts.
## Primary Indications
* Symptomatic relief of gastrointestinal and biliary spasm.
* Palliative care: Management of "death rattle" (respiratory tract secretions).
* Adjunct in diagnostic imaging (e.g., radiology of the GI tract).
## Adult Dosing
* **Oral:** 20 mg up to 4 times daily. Max: 80 mg/day.
* **IM/Slow IV:** 20 mg as a single dose; may repeat after 30 minutes if necessary. Max: 100 mg/day.
* **Palliative Care (off-label):** 10–20 mg SC up to every 4 hours or via continuous SC infusion (60–120 mg/24 hours).
## Pediatric Dosing
* **Children ≥ 6 years:** 10 mg orally up to 3 times daily.
* **IV/IM use in children:** Use is generally limited and lacks robust standardization. Refer to local pediatric formularies or hospital protocols.
* **Not recommended for children under 6 years.**
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal standardized adjustment, but use with caution; initiate at a lower dose if clinical signs of impaired clearance are present.
* **Elderly:** Use caution due to increased sensitivity to anticholinergic effects (urinary retention, constipation).
## Contraindications
* Hypersensitivity to hyoscine butylbromide.
* Myasthenia gravis.
* Megacolon.
* Paralytic ileus or mechanical intestinal obstruction.
* Narrow-angle glaucoma.
* Tachycardia/Tachyarrhythmias.
* Prostatic hypertrophy with urinary retention.
## Adverse Effects
* **Common:** Dry mouth, tachycardia, blurred vision (mydriasis), constipation, urinary retention.
* **Serious:** Anaphylaxis, cardiac arrhythmias (following IV administration), precipitation of acute glaucoma.
## Key Drug Interactions
* **Anticholinergics:** Additive effects (increased risk of dry mouth, urinary retention, sedation).
* **Antipsychotics/Antidepressants:** May increase anticholinergic side effects.
* **Metoclopramide:** Antagonistic effects on GI motility; monitor efficacy if co-prescribed.
## Monitoring
* Monitor heart rate, especially after IV administration.
* Monitor for signs of urinary retention.
* In palliative care, monitor respiratory secretions and depth/rate of respiration.
## Clinical Pearls
* **IV Administration:** Administer slowly to avoid transient tachycardia or hypotension.
* **Systemic Effects:** Because it is poorly absorbed orally (low bioavailability), the systemic antimuscarinic side effects are generally lower than those of atropine or hyoscine hydrobromide.
* **Palliative Care:** Effectively reduces secretions without causing the severe confusion associated with hyoscine hydrobromide.
* **Administration:** When used for diagnostic procedures, the effect typically lasts 20–30 minutes.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug dosing, indications, and safety data can change. Always verify current prescribing information using local institutional formularies, the *British National Formulary (BNF)*, or the specific manufacturer's summary of product characteristics before prescribing or administering medication.
